![https://static.aminer.cn/upload/avatar/409/1987/445/54058b67dabfae91d3fefc16_0.jpg](https://avatarcdn.aminer.cn/upload/avatar/409/1987/445/54058b67dabfae91d3fefc16_0.jpg!160)
Gottfried Baier
Professor
Institute of Cell Genetics
Department for Pharmacology and Genetics, Medical University of Innsbruck;Christian Doppler Laboratory for Pharmacological Cancer Immunotherapy, Medical University of Innsbruck;Division for Translational Cell Genetics, Department for Pharmacology and Genetics, Medical University of Innsbruck;Institute for Translational Cell Genetics;Division for Cell Genetics, Medical University of Innsbruck
Follow
Claim
分享
Follow
Claim
分享
基本信息
views: 90
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Research of his laboratory is focusing on molecular mechanisms signaling mediating tolerance induction versus clonal expansion of T lymphocyte. His team has initially focused on the physiological involvement of distinct PKC isotypes in specific immune cell functions, employing a set of single- and double PKC isotype gene
knockout mice as well as specific and potent low molecular weight inhibitors generated by his BigPharma and SME partners. His achievements include the leading-edge discoveries of the central-staged PKC/Cbl-b and
PKC/NR2F6 signaling pathways and their key role in the control of cancer immunity. Genetic blocking experiments have shown promising improvements in anti-tumour T cell responses, thereby validating particularly NR2F6 as an alternative and druggable cancer therapeutic candidate drug target for next-generation immune-oncology regimens.
knockout mice as well as specific and potent low molecular weight inhibitors generated by his BigPharma and SME partners. His achievements include the leading-edge discoveries of the central-staged PKC/Cbl-b and
PKC/NR2F6 signaling pathways and their key role in the control of cancer immunity. Genetic blocking experiments have shown promising improvements in anti-tumour T cell responses, thereby validating particularly NR2F6 as an alternative and druggable cancer therapeutic candidate drug target for next-generation immune-oncology regimens.
Research Interests
Papers共 165 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Immunology (2024)
Miriam Bosch,Nina Kallin,Sainitin Donakonda,Jitao David Zhang,Hannah Wintersteller,Silke Hegenbarth,Kathrin Heim,Carlos Ramirez, Anna Fürst, Elias Isaac Lattouf,Martin Feuerherd, Sutirtha Chattopadhyay,
Biomoleculesno. 11 (2023): 1599-1599
Science advancesno. 27 (2023)
biorxiv(2022)
Cancer immunology researchno. 4 (2022): 370-370
Load More
Author Statistics
#Papers: 171
#Citation: 8897
H-Index: 44
G-Index: 91
Sociability: 6
Diversity: 0
Activity: 0
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn